Semaglutide has been approved for treating MASH (fatty liver disease with inflammation), marking a major expansion of GLP-1 peptide therapeutics into liver disease treatment.
Approved for MASH treatmentSemaglutide is now one of only two approved drugs for non-cirrhotic MASH with moderate-to-advanced fibrosis, adding liver disease to its growing list of approved indications.
What the researchers found
Semaglutide has demonstrated efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH), resolving steatohepatitis and improving hepatic fibrosis. It has been approved alongside resmetirom for treating non-cirrhotic MASH with moderate-to-advanced fibrosis. The review traces semaglutide's development from the discovery of GLP-1's role in glucose homeostasis through to its expanding clinical applications, which now include glycemic control, weight reduction, cardiovascular risk reduction, and liver disease treatment.
Why it matters
MASH (formerly NASH) is the most common liver disease worldwide and a leading cause of liver transplantation. Until recently, there were no approved drug treatments. Semaglutide's approval for MASH represents a major expansion of GLP-1 peptide therapeutics into liver disease, demonstrating that this peptide drug class has effects far beyond diabetes and obesity management.
The numbers in context
Review covers GLP-1 RA development: exenatide → liraglutide → dulaglutide → semaglutide → tirzepatide · semaglutide approved for MASH with moderate-to-advanced fibrosis · weekly subcutaneous or oral formulation
How the study worked
This is a narrative review covering the pharmacology of GLP-1 and semaglutide, its mechanism of action, clinical trial evidence for MASH treatment, safety profile, and comparison with other MASH therapeutic approaches.
Who was studied
Review covering patients with MASH, type 2 diabetes, and obesity treated with semaglutide
What this study cannot tell us
As a narrative review, it does not systematically evaluate all available evidence. Semaglutide's approval for MASH is relatively recent, so long-term outcomes and optimal treatment duration are not yet established. The review does not quantify the magnitude of fibrosis improvement or steatohepatitis resolution rates in detail. Head-to-head comparisons with resmetirom are limited.
How to read the evidence
This is a narrative review summarizing clinical trial evidence that led to semaglutide's regulatory approval for MASH. The underlying approval was based on phase III clinical trial data, representing high-quality evidence.
When this study was published
Published in 2025, this review reflects the latest approved indication for semaglutide and provides a current overview of its clinical evidence for liver disease.
The bigger picture
Semaglutide's approval for MASH exemplifies the remarkable therapeutic expansion of GLP-1 peptide drugs. Originally developed for type 2 diabetes, they've since been approved for obesity, cardiovascular risk reduction, and now liver disease. This trajectory suggests GLP-1 receptor agonists may be among the most versatile drug classes in modern medicine, with ongoing research exploring benefits for kidney disease, Alzheimer's, and addiction.
Questions still open
- How does semaglutide compare to resmetirom in head-to-head trials for MASH treatment?
- What is the optimal duration of semaglutide treatment for MASH, and does fibrosis improvement persist if the drug is stopped?
- Could combining semaglutide with resmetirom or other MASH therapies produce superior outcomes through complementary mechanisms?
Common questions
What is MASH and why is it so important?
How does a diabetes drug help treat liver disease?
Read the original research
Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
Cureus, 17(10), e95632
Citation
Zacharia, George S; Gongati, Sudharsan R; Kharel, Aayush; Jacob, Anu. (2025). Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.. Cureus, 17(10), e95632. https://doi.org/10.7759/cureus.95632